Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 12/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.54 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.54 |
| ▸ | BCHE | P06276 | 4/20 | 0.54 |
| ▸ | ACHE | P22303 | 4/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17788587 | 0.84 | KDM4E (0.55) | ALDH1A1GAAMAPTBCHEKDM4E | |
| SCHEMBL10245660 | 0.83 | HTT (0.57) | ALDH1A1GAAMAPTHTTKDM4E | |
| SCHEMBL17788600 | 0.82 | PDCD1LG2 (0.50) | ALDH1A1GAAMAPTHTTCHRM2 | |
| SCHEMBL13900365 | 0.81 | MTNR1A (0.57) | ALDH1A1GAACHRM2GRIN1GRIN2A | |
| SCHEMBL22548784 | 0.81 | KDM4E (0.49) | ALDH1A1GAAHTTBCHEACHE | |
| SCHEMBL22957883 | 0.80 | RIPK1 (0.62) | ALDH1A1HTTKDM4ECYP2D6L3MBTL1 | |
| SCHEMBL13875905 | 0.80 | HTT (0.51) | HTTCYP3A4CYP2D6 | |
| SCHEMBL22957772 | 0.80 | HTT (0.51) | ALDH1A1GAAMAPTHTTACHE | |
| SCHEMBL19301878 | 0.80 | ABCB1 (0.62) | ALDH1A1GAAHTTBCHE | |
| SCHEMBL5695121 | 0.79 | ALDH1A1 (0.79) | ALDH1A1GAAMAPTCHRM2GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | Epizyme, Inc. | 2021-07-15 | — | — | US | disclosed |
| US-20210198277-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2021-07-01 | — | — | US | disclosed |
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200113901-A1 | METHODS OF USING EHMT2 INHIBITORS | Epizyme, Inc. | 2020-04-16 | — | — | US | disclosed |
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2020-02-20 | — | — | US | disclosed |
| US-9914740-B2 | Tricyclic pyrido-carboxamide derivatives as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-13 | — | — | US | disclosed |
| US-20090011977-A1 | Novel Lipopeptides as Antibacterial Agents | HILL JASON | 2009-01-08 | — | — | US | disclosed |
| US-20080287347-A1 | Novel Lipopeptides as Antibacterial Agents | CUBIST PHARMACEUTICALS, INC. | 2008-11-20 | — | — | US | disclosed |
| US-7408025-B2 | Lipopeptides as antibacterial agents | CUBIST PHARMACEUTICALS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-7326703-B2 | (1,10B-Dihydro-2-(aminocarbonyl-phenyl)-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors | TIBOTEC PHARMACEUTICALS LTD (IL) | 2008-02-05 | — | — | US | disclosed |
| US-20070248624-A1 | (1,10B-Dihydro-2-(Aminocarbonyl-Phenyl)-5h-Pyrazolo[1,5-C][1,3]Benzoxazin-5-Yl)Phenyl Methanone Derivatives as Hiv Viral Replication Inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2007-10-25 | — | — | US | disclosed |
| US-7247725-B2 | Gamma-aminoamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7235541-B2 | Neurokinin antagonists for use as medicaments | ASTRAZENECA AB (SE) | 2007-06-26 | — | — | US | disclosed |
| US-7235541-B2 | Neurokinin antagonists for use as medicaments | ASTRAZENECA AB (SE) | 2007-06-26 | — | — | US | disclosed |
| US-20070021406-A1 | New neurokinin antagonists for use as medicaments | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021406-A1 | New neurokinin antagonists for use as medicaments | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | ALDH1A1 430/4885GAA 2676/4885MAPT 2065/4885 |
| US-20210198277-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | SHMT1, BHMT, BHMT2 | ALDH1A1 185/4885GAA 637/4885MAPT 3035/4885 |
| US-20080287347-A1 | Novel Lipopeptides as Antibacterial Agents | CLPTM1, NGLY1, VIP | ALDH1A1 4742/4885GAA 1055/4885MAPT 4381/4885 |
| US-20070021406-A1 | New neurokinin antagonists for use as medicaments | NPSR1, HRH4, OPRL1 | ALDH1A1 2402/4885GAA 1466/4885MAPT 908/4885 |
| US-20090011977-A1 | Novel Lipopeptides as Antibacterial Agents | CLPTM1, NGLY1, VIP | ALDH1A1 4742/4885GAA 1055/4885MAPT 4381/4885 |
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | ALDH1A1 430/4885GAA 2676/4885MAPT 2065/4885 |
| US-20070248624-A1 | (1,10B-Dihydro-2-(Aminocarbonyl-Phenyl)-5h-Pyrazolo[1,5-C][1,3]Benzoxazin-5-Yl)Phenyl Methanone Derivatives as Hiv Viral Replication Inhibitors | POLRMT, MAVS, DHX15 | ALDH1A1 789/4885GAA 1809/4885MAPT 2629/4885 |
| US-20200113901-A1 | METHODS OF USING EHMT2 INHIBITORS | EHMT2, EHMT1, BHMT | ALDH1A1 662/4885GAA 983/4885MAPT 2389/4885 |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | EHMT2, BHMT, SHMT2 | ALDH1A1 430/4885GAA 2676/4885MAPT 2065/4885 |
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | ALDH1A1 4194/4885GAA 4104/4885MAPT 1730/4885 |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | EHMT2, BHMT2, BHMT | ALDH1A1 799/4885GAA 2832/4885MAPT 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.